Latin-American Von Willebrand Disease Registry

计划入组 500 人 · 首次发布于 2020 年 2 月 21 日

Von Willebrand Disease in the Netherlands

计划入组 1,100 人 · 首次发布于 2018 年 5 月 11 日

Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador

计划入组 81 人 · 首次发布于 2012 年 5 月 2 日

Von Willebrand factor human(Vonvendi, Wilate)

Antihemophilic factor, human recombinant(Advate, Adynovate, Helixate, Kogenate, Kovaltry, Novoeight, Recombinate, Helixate NexGen)

von Willebrand factor concentrate

Menarini - Von Heyden GmbH

Germany

Otto-von-Guericke-Universität Magdeburg

Germany

Carl von Ossietzky Universität Oldenburg

Germany

Star Therapeutics Secures $125M Series D to Advance Von Willebrand Disease Drug VGA039 Through Phase 3 Testing

Star Therapeutics Receives FDA Rare Pediatric Disease and Breakthrough Therapy Designations for VGA039 in Von Willebrand Disease

Star Therapeutics' VGA039 Receives FDA Fast Track Designation for Von Willebrand Disease